Brief Article
Copyright ©2014 Baishideng Publishing Group Co.
World J Diabetes. Feb 15, 2014; 5(1): 69-75
Published online Feb 15, 2014. doi: 10.4239/wjd.v5.i1.69
Table 1 Characteristics of the patient population, as grouped according to the four algorithms
nGenderAge (yr)Weight (kg)BMI (kg/m2)Duration (yr)Baseline A1CBaseline FPG (mg/dL)Previous treatment
Fixed titration 2/2 U
LANMET268 M55.0 ± 1078 ± 16.630.7 ± 4.958 ± 4.239.39% ± 1.67%193.0 ± 59.42 OAD (20) 1 OAD (6)
Variable titration
LANMET PLUS226 M52.3 ± 7.770.6 ± 1327.8 ± 4.77.8 ± 3.89.35% ± 1.34%179.4 ± 51.42 OAD (21) 1 OAD (1)
Fixed titration 2/2 U
DeGold2314 M54.6 ± 878.3 ± 13.528.8 ± 4.410.2 ± 7.19.21% ± 1.30%196.6 ± 54.82 OAD (19) 1 OAD (4)
Variable titration
DeGold PLUS2112 M53.8 ± 7.679.3 ± 15.929.5 ± 4.49.8 ± 5.49.61% ± 1.69%196.1 ± 53.42 OAD (19) 1 OAD (2)
Table 2 Treatment algorithms used in this study
Initial doseBMIAlgorithms
LANMET fixedLANMETPlusDeGold fixedDeGoldPlus
Fixed initial dose in Un.a.1010
Variable dose according to< 260.20.2
BMI (kg/m2) in U/kg26 < 300.250.25
30 < 350.30.3
> 350.350.35
Insulin adjustmentFPG
Fixed Titration twice/week in U22
Variable titration according to< 10000
FPG (mg/dL) twice/week in U101 < 120-2-2
121 < 14022
141 < 18044
> 180-2-2
Table 3 Treatment efficacy data n (%)
LANMETLANMET PLUSDeGoldDeGold PLUS
Initial insulin dose (U)10.0 ± 010.0 ± 021.0 ± 7.318.3 ± 7.0
Initial insulin dose (U/kg)0.13 ± 0.020.13 ± 0.030.26 ± 0.050.25 ± 0.05
Final insulin dose (U)41.65 ± 14.0087.00 ± 26.8754.68 ± 21.6348.19 ± 38.50
Final insulin dose (U/kg)0.54 ± 0.200.59% ± 0.27%0.67% ± 0.24%0.65% ± 0.52%
Baseline A1C9.39% ± 1.67%9.35% ± 1.34%9.21% ± 1.30%9.61% ± 1.69%
Final A1C7.36% ± 1.32%7.32% ± 0.67%6.82% ± 0.70%7.38% ± 0.95%
Reduction in A1C2.02% ± 1.60%2.02% ± 1.17%2.48% ± 1.23%2.23% ± 1.69%
Proportion of patients reaching FPG target19/26 (73)16/20 (80)22/23 (95)20/21 (95)
Proportion of patients reaching A1C ≤ 7.5%17/26 (65)13/20 (65)20/23 (87)13/21 (62)
Proportion of patients reaching A1C ≤ 7.0%11/26 (42)5/20 (25)16/23 (69)7/21 (33)
Duration of titration to reach FPG target (d)28 ± 3115 ± 1922 ± 2020 ± 17
Weight variation (kg)0.276 ± 2.941.190 ± 2.4300.954 ± 2.5901.630 ± 2.500
Final FPG (mg/dL)119.4 ± 36.2109.0 ± 28.7106.6 ± 18.0107.6 ± 17.3
Table 4 Hypoglycemia events n (%)
LANMETLANMETPLUSDeGoldDeGoldPLUSLANMET andLANMET PLUS
DeGold andDeGold PLUS
LANMETand DeGold
LANMET PLUSand DeGold PLUS
Fixed initial doseVariable initial doseFixed titrationVariable titration
Patients with moderate or severe hypoglycemia (n)7 (27)6 (30)5 (22)5 (23)13 (28)10 (23)12 (25)11 (27)
Number of moderate or severe hypoglycemia events102252032251542
Patients with symptomatic night hypoglycemia (n)13 (50)4 (15)5 (22)4 (19)17 (37)9 (20)18 (37)8 (19)
Number of nocturnal symptomatic hypoglycemia events46169862173125
Patients presenting any type of hypoglycemia (n)16 (61)14 (70)15 (68)12 (57)30 (65)27 (62)31 (64)26 (60)
Number of any type of hypoglycemia events11310748111220159157155